Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CGEN Stock Forecast 2026-2027
$2.82
Current Price
$267.82M
Market Cap
Buy 6
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to CGEN Price Targets
+361.0%
To High Target of $13.00
+41.8%
To Median Target of $4.00
+41.8%
To Low Target of $4.00
CGEN Price Momentum
+2.2%
1 Week Change
+34.9%
1 Month Change
+91.8%
1 Year Change
+84.3%
Year-to-Date Change
-4.1%
From 52W High of $2.94
+129.3%
From 52W Low of $1.23
📊 TOP ANALYST CALLS
Did CGEN Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Compugen is one of their latest high-conviction picks.
Latest CGEN Stock Price Targets & Analyst Predictions
Based on our analysis of 11 Wall Street analysts, CGEN has a bullish consensus with a median price target of $4.00 (ranging from $4.00 to $13.00). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $2.82, the median forecast implies a 41.8% upside. This outlook is supported by 6 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Tony Butler at EF Hutton, projecting a 361.0% upside. Conversely, the most conservative target is provided by Swayampakula Ramakanth at HC Wainwright & Co., suggesting a 41.8% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CGEN Analyst Ratings
6
Buy
0
Hold
0
Sell
CGEN Price Target Range
Low
$4.00
Average
$4.00
High
$13.00
Current: $2.82
Latest CGEN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CGEN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 7, 2026 | Lake Street | Chad Messer | Buy | Initiates | $6.00 |
| Jan 7, 2026 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Initiates | $4.00 |
| May 21, 2024 | Truist Securities | Asthika Goonewardene | Buy | Maintains | $4.00 |
| Mar 8, 2024 | Truist Securities | Asthika Goonewardene | Buy | Maintains | $5.00 |
| Dec 19, 2023 | Stifel | Stephen Willey | Buy | Maintains | $4.00 |
| Aug 23, 2023 | Truist Securities | Asthika Goonewardene | Buy | Reiterates | $4.00 |
| Aug 7, 2023 | EF Hutton | Buy | Reiterates | $N/A | |
| Jun 6, 2023 | EF Hutton | Tony Butler | Buy | Reiterates | $13.00 |
| May 26, 2023 | EF Hutton | Tony Butler | Buy | Reiterates | $13.00 |
| May 24, 2023 | EF Hutton | Tony Butler | Buy | Reiterates | $13.00 |
| May 16, 2023 | Oppenheimer | Mark Breidenbach | Outperform | Maintains | $7.00 |
| Feb 28, 2023 | Oppenheimer | Mark Breidenbach | Outperform | Reiterates | $8.00 |
| Feb 8, 2023 | Jefferies | Chris Howerton | Underperform | Downgrade | $0.50 |
| Jan 5, 2023 | EF Hutton | Tony Butler | Buy | Initiates | $13.00 |
| Nov 15, 2022 | Oppenheimer | Mark Breidenbach | Outperform | Maintains | $8.00 |
| Aug 23, 2022 | Truist Securities | Asthika Goonewardene | Buy | Maintains | $4.00 |
| Aug 8, 2022 | JMP Securities | Reni Benjamin | Market Outperform | Maintains | $4.00 |
| Aug 8, 2022 | Oppenheimer | Mark Breidenbach | Outperform | Maintains | $12.00 |
| Aug 5, 2022 | Jefferies | Hold | Downgrade | $N/A | |
| Feb 25, 2022 | Oppenheimer | Mark Breidenbach | Outperform | Maintains | $14.00 |
Compugen Ltd. (CGEN) Competitors
The following stocks are similar to Compugen based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Compugen Ltd. (CGEN) Financial Data
Compugen Ltd. has a market capitalization of $267.82M with a P/E ratio of 7.6x. The company generates $72.76M in trailing twelve-month revenue with a 48.6% profit margin.
Revenue growth is +4,477.3% quarter-over-quarter, while maintaining an operating margin of +83.2% and return on equity of +44.8%.
Valuation Metrics
Market Cap
$267.82M
Enterprise Value
$130.58M
P/E Ratio
7.6x
PEG Ratio
0.0x
Price/Sales
3.8x
Growth & Margins
Revenue Growth (YoY)
+4,477.3%
Gross Margin
+94.7%
Operating Margin
+83.2%
Net Margin
+48.6%
EPS Growth
+4,477.3%
Financial Health
Cash/Price Ratio
+54.6%
Current Ratio
6.6x
Debt/Equity
2.9x
ROE
+44.8%
ROA
+14.4%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Compugen Ltd. (CGEN) Business Model
About Compugen Ltd.
What They Do
Develops AI-driven cancer immunotherapy solutions.
Business Model
Compugen Ltd. generates revenue by advancing its proprietary immunotherapy programs through clinical stages and partnering with other pharmaceutical companies. Its primary assets include wholly owned clinical programs like COM701 and COM902, which target specific cancer pathways. Additionally, the company collaborates with partners such as AstraZeneca and Gilead to develop bispecific antibodies and other therapeutic agents.
Additional Information
The company is at the forefront of utilizing artificial intelligence and machine learning for drug target discovery, which enhances its pipeline of potential therapies. With a strategic focus on overcoming cancer resistance mechanisms, Compugen Ltd. is positioned to innovate in the oncology field. The company's headquarters in Israel and presence in San Francisco highlight its global reach and commitment to advancing cancer treatment.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
75
CEO
Dr. Eran Ophir Ph.D.
Country
Israel
IPO Year
2000
Website
cgen.comCompugen Ltd. (CGEN) Latest News & Analysis
Latest News
Quick Summary
Compugen Ltd. (NASDAQ: CGEN) will present at the 25th Annual Needham Virtual Healthcare Conference, highlighting its focus on cancer immunotherapy and target discovery.
Why It Matters
Compugen's presentation at a major healthcare conference can boost visibility, attract investor interest, and potentially lead to partnerships, impacting stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Compugen Ltd. (CGEN) held its Q4 2025 earnings call, providing insights into financial performance and future outlook. Specific details on earnings and guidance were discussed.
Why It Matters
The Q4 2025 earnings call provides insight into Compugen Ltd.'s financial performance, strategic direction, and future growth prospects, influencing investor sentiment and stock valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Compugen Ltd. strengthened its financial position via a non-dilutive deal with AstraZeneca, extending cash runway to 2029. Leadership changes were made, and clinical trials for COM701 and GS-0321 are advancing.
Why It Matters
Compugen's non-dilutive transaction enhances financial stability, extends cash runway, and new leadership signals strategic growth. Promising clinical updates could boost investor confidence and stock value.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Compugen (CGEN) reported quarterly earnings of $0.60 per share, exceeding the Zacks Consensus Estimate of $0.05, and improved from a loss of $0.07 per share a year prior.
Why It Matters
Compugen's strong earnings beat signals improved financial performance, potentially boosting investor confidence and driving stock price appreciation. Positive momentum may attract more investment.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Compugen is rated a 'Buy' due to pipeline advancements, pharma partnerships, and a cash runway until 2029. Key developments include the MAIA trial and a deal with AstraZeneca for financial stability.
Why It Matters
Compugen's strong pipeline, extended cash runway, and strategic partnerships enhance its growth potential, making it a favorable investment amid upcoming clinical trial milestones.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Compugen Ltd. (NASDAQ: CGEN) will participate in the Oppenheimer and Leerink Partners healthcare conferences on Feb 26 and Mar 9, 2026, respectively, with live webcasts available on their website.
Why It Matters
Compugen's participation in key investor conferences highlights its engagement with the investment community, potentially boosting interest and stock liquidity. The focus on cancer immunotherapy and AI/ML may attract investors looking for innovative biotech opportunities.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About CGEN Stock
What is Compugen Ltd.'s (CGEN) stock forecast for 2026?
Based on our analysis of 11 Wall Street analysts, Compugen Ltd. (CGEN) has a median price target of $4.00. The highest price target is $13.00 and the lowest is $4.00.
Is CGEN stock a good investment in 2026?
According to current analyst ratings, CGEN has 6 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $2.82. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CGEN stock?
Wall Street analysts predict CGEN stock could reach $4.00 in the next 12 months. This represents a 41.8% increase from the current price of $2.82. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Compugen Ltd.'s business model?
Compugen Ltd. generates revenue by advancing its proprietary immunotherapy programs through clinical stages and partnering with other pharmaceutical companies. Its primary assets include wholly owned clinical programs like COM701 and COM902, which target specific cancer pathways. Additionally, the company collaborates with partners such as AstraZeneca and Gilead to develop bispecific antibodies and other therapeutic agents.
What is the highest forecasted price for CGEN Compugen Ltd.?
The highest price target for CGEN is $13.00 from Tony Butler at EF Hutton, which represents a 361.0% increase from the current price of $2.82.
What is the lowest forecasted price for CGEN Compugen Ltd.?
The lowest price target for CGEN is $4.00 from Swayampakula Ramakanth at HC Wainwright & Co., which represents a 41.8% increase from the current price of $2.82.
What is the overall CGEN consensus from analysts for Compugen Ltd.?
The overall analyst consensus for CGEN is bullish. Out of 11 Wall Street analysts, 6 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $4.00.
How accurate are CGEN stock price projections?
Stock price projections, including those for Compugen Ltd., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 20, 2026 2:26 AM UTC